ENCELL Co., Ltd. makes
a positive difference in the world
through the development of
innovative pharmaceutical products.

Mission & Vision

CGT CDMO Services
  • 01
    A Leading Global CDMO Company Representing Korea
    Expanding capabilities + capacity
  • 02
    Optimized GMP Technology
    Maximizing Manufacturing and Quality Control Capabilities
  • 03
    Comprehensive CDMO
    A domestic leader in multi-product advanced biopharmaceuticals
Next Generation
Stem Cell Therapy
  • 01
    Global, Unique
    The world's only early-stage mesenchymal stem cell therapy
  • 02
    First-in-Class
    Targeted stem cell therapy for muscle disease
  • 03
    Development stage treatments for rare diseases
    Charcot-Marie-Tooth disease (CMT) + Duchenne muscular dystrophy (DMD)

Timeline

  • 2021 - Present

    Established as a leader in cell and gene therapy development

  • 2018 ~ 2020

    Marking the corporate growth and technological advancement of ENCELL Co., Ltd..

  • 2023
    06
    DMD Repeat Dosing Phase 1b/2a Clinical Trial IND approval
    Selected for National New Drug Development Project
    05
    Completed Phase 1 clinical trials for CMT and DMD
    Received GMP license for 2nd cell processing facility
    04
    Selected for Korean Fund for Regenerative Medicine (KFRM)
    Development Project Selected for Bio-Healthcare Technology Development Project
    02
    Submitted IND for CMT Repeat Dosing Phase 1b/2a Clinical Trial
  • 2022
    12
    Received the Minister's Award from the Ministry of Trade, Industry and Energy (Job Creation Category)
    09
    Obtained GMP License for Advanced Biopharmaceutical Manufacturing (Facility 2, 3)
    08
    Obtained GMP License for Advanced Biopharmaceutical Manufacturing (Facility 1)
    07
    Designated as a development stage orphan drug (CMT)
    05
    Secured first AAV manufacturing contract
    Successfully raised KRW 24.2 billion in pre-IPO investment
    04
    Designated as a Development-Stage Rare Disease Drug (DMD)
    Established KYMRIAH® Korea CCPC Facility (GMP Facility 2)
    02
    Completed first patient dosing for CMT clinical trial
    01
    Selected by MFDS for 2022 First-Year Application Research Project(Development of quality and safety evaluation technology for cancer immunogen/cell therapy)
    GMP facility 3 completed
    First patient administration for DMD clinical trial completed
  • 2021
    12
    Received the Minister's Award from the Ministry of SMEs and Startups for contribution to startup promotion
    Held Phase 1 Clinical Trial Initiation Meeting for Charcot-Marie-Tooth Disease
    Held Phase 1 Clinical Trial Initiation Meeting for Duchenne Muscular Dystrophy
    11
    Received Minister's Award from the Ministry of Health and Welfare for Contributions to the Advancement of Medical Technology
    10
    Completed GMP Facility 2 (Hanam)
    06
    Received IND approval for Phase 1 clinical trial of next-generation stem cell therapy for Charcot-Marie-Tooth
    diseaseObtained "Cell Processing Facility" certification from MFDS (No. 10)
    05
    Received IND approval for Phase 1 clinical trial of stem cell therapy for Duchenne Muscular Dystrophy
    Successfully secured KRW 25.6 billion Series B investment
    03
    Obtained "Human Cell Management Business" certification from MFDS (No. 4)
    01
    Designated as a CPC (Cell Processing Center) for Novartis CAR-T Therapy.
  • 2020
    12
    Designated as CCPC (Central Cell Processing Center) for Ansen CAR-T Therapy
    09
    Selected as a Bio-Innovative Growth Enterprise by the Ministry of Trade, Industry and Energy
    08
    GMP Facility 1 (Seoul) certified with ISO 900 (Received certification in 2015)
    07
    Selected for SME Collabo R&D Project
    05
    Signed Strategic Technology Partnership with ThermoFisher Scientific™.
    02
    Successfully secured KRW 10.1 billion Series A investment
    Commenced planning for GMP Facility 2 (Hanam).
  • 2019
    08
    Purchase of land for construction of GMP facility 2 (Hanam)
    07
    Selected for Excellence by Korea Health Industry Development Institute
  • 2018
    08
    Passed GMP inspection by MFDS
    07
    Selected for TIPS Program
    05
    Commenced CMO business through a contract with Hanmi Pharmaceutical for cancer gene and stem cell therapies
    03
    Established the company
    Headquarters: 6th floor, WE Tower, Cheongdam-dong
    GMP Facility 1: Samsung Medical Center, Mirae Medical Research Building
    02
    Approved for spin-off from Samsung Medical Center